Benralizumab is effective in treating eosinophilic asthma. It also improves the quality of life of individuals with poorly controlled asthma. Breathlessness, recurrent exacerbations, and decreased quality of life are prevalent in individuals with severe asthma despite high-dose corticosteroids. The hallmarks of severe eosinophilic asthma include eosinophilic airway infiltration, inflammation, blockage, or constriction. Benralizumab, an anti-IL-5Ra,...